Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
CONCLUSIONS: There is high-certainty evidence that 5-ASA is superior to placebo for maintenance therapy in UC. There is high-certainty evidence that 5-ASA is inferior compared to SASP. There is probably little or no difference between 5-ASA and placebo, and 5-ASA and SASP in commonly reported AEs such as flatulence, abdominal pain, nausea, diarrhea, headache, and dyspepsia. Oral 5-ASA administered once daily has a similar benefit and harm profile as conventional dosing for maintenance of remission in quiescent UC.
PMID: 32856298 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK Tags: Cochrane Database Syst Rev Source Type: research
More News: Asacol | Conferences | Databases & Libraries | Dyspepsia | Eyes | General Medicine | Headache | Inflammatory Bowel Disease | Lialda | Migraine | Pain | Study | Ulcerative Colitis